SPDL1 and non-small cell lung carcinoma: In NSCLC patients, high levels of sPD-L1 were associated with a shortening of progression-free survival and overall survival (HR = 1.81, 95% CI 1.09–3.00, p = 0.02 OS; HR = 2.18, 95% CI 1.27–3.76, p < 0.01 for PFS) [11].